New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing promising outcomes in managing excess mass and type 2 diabetes. Initial evidence suggest a novel action contributing to considerable https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/